

QIBA Ultrasound Shear Wave Speed (SWS) Biomarker Committee (BC)

Friday, February 26, 2016; 11 AM CT

Draft Call Summary

In attendance

Tim J. Hall, PhD (Co-Chair)
Brian Garra, MD (Co-Chair)
S. Kaisar Alam, PhD
Michael André, PhD
Jun Chen, PhD
Shigao Chen, PhD
Yuling Chen, PhD

Wui K. Chong, MD
Mathieu Couade, PhD
Manish Dhyan, MD
Steven Fick, PhD
Joel Gay, MSc
Mike MacDonald, PhD
Ravi Managuli, PhD, RDMS

Svetoslav Nikolov, PhD
Mark Palmeri, MD, PhD
Stephen Rosenzweig, PhD
Theresa Tuthill, PhD
Michael Wang, PhD, MASC
Keith Wear, PhD
James Zagzebski, PhD

RSNA

Joe Koudelik
Julie Lisiecki

Moderator: Dr. Hall

Review of January 22nd US SWS BC call notes

- Notes were approved as written

Round 6 Request for Proposals

- The primary goal for QIBA is to advance / enhance the Profile documents or conformance per NIBIB objectives
- While human studies / clinical work cannot be funded, anything leading up to a protocol for a clinical trial, including clinical performance or clinical efficacy, could be considered
- Project ideas are encouraged for open discussion on future calls

Phantoms Update

- Currently, the phantoms are in Europe for their final scans, under the supervision of Remi Souchon
- Due to some recent QIDW technical difficulties, Dr. Palmeri set up an additional location to access data as follows:
 - <https://duke.box.com/QIBA-DigitalPhantoms>
- Calibrated phantoms for bias and variance may be needed
- Systems standards and protocols will be added

Profile for US SWS

- The Profile writing team plans to release the first draft prior to the QIBA Annual Meeting, for internal review
 - Supporting data are still needed; Dr. Palmeri's expertise will be needed to fill in remaining gaps, such as:
 - An estimation of the time and effort needed to determine necessary metrics
 - Instructions on how to process and report the data
 - Remaining manufacturer and regulatory issues that need to be addressed
- Cross-scanner standardization methods still need to be addressed in the Profile
- Once internal review is complete, the Profile may be released for Public Comment with open issues
 - Comments may be left open for resolution with groundwork studies, as needed
 - Limited multi-site trials or feasibility tests may be conducted with BC team members
- A European / Japanese clinical trial collaboration is under consideration for technical validation of the Profile
 - Additional questions must be answered before considering this step

QIBA Annual Meeting

- Though attendance is restricted to PIs and QIBA leadership, Dr. Garra asked for permission to bring 1 – 2 guests (local colleagues who may use QIBA tools clinically)
 - They would primarily be interested in liver forums

QIBA f2f Meeting at AIUM

- The QIBA US Volume Blood Flow BC is scheduled to meet at AIUM on Saturday, March 19th from 4 – 6 pm, local time, to work on their Profile
- No further details are available at this time. **AIUM contact:** Kathi Minton (kminton@aium.org)

Recording

- Dr. Hall briefly mentioned that the QIBA Steering Committee is looking for a test group for recording WebEx calls for QIBA Japanese colleagues
- No objections were raised, and Dr. Alam noted that no proprietary information is shared on calls, though the aim of WebEx calls is live participation, which is what makes the use of WebEx invaluable

Action item:

- All to consider potential Round 6 projects
- Dr. Hall to follow up with Dr. Jackson regarding what is/not within Round-6 project scope regarding clinical studies (i.e., what is allowed: preparing imaging protocols, analyzing data, etc.)

Meetings: (Fridays, 11 am CT):

March:

- Mar 11: Clinical Task Force
- [3/ 14–16: ISTU \(Tel Aviv, Israel\)](#)
- [3/ 17–21: AIUM \(New York, NY\)](#)
- **Mar 18: No call {ISTU / AIUM conventions}**
- Mar 25: US SWS BC

April:

- Apr 01: Systems/ Phantom Task Force
- Apr 08: Clinical Task Force
- **Apr 15: No call**
- Apr 22: US SWS BC
- **Apr 29: No call**